Kornimate/medical-research-clean huggingface dataset:
clinical and radiographic evaluation of dental implants installed between 2004 and 2010

Conditions: Dental Implant Failed

Summary: the convenience sample to be included in the present study will consist of all individuals who had implants installed at the dentistry clinic of the university santo amaro, between the years 2004 and 2010. the following criteria will be evaluated: age; sex; presence of systemic disease; area in which the implant was installed; implant diameter and height; type of prosthesis installed; presence of bone resorption and annual maintenance.

the control of biofilm around implants is fundamental to the success of implant therapy, and it is the duty of the dentist to inform, guide and maintain patients in order to avoid pathological processes that may lead to the loss of the implanted component. the objective of the present study will be to evaluate by clinical and radiographic parameters the condition of oral implants placed for more than five years. the convenience sample to be included in this study will be composed of all individuals who had implants installed at the dental clinic of the university santo amaro, between 2004 and 2010. the following criteria will be evaluated: age; sex; presence of systemic disease; area in which the implant was installed; implant diameter and height; type of prosthesis installed; presence of bone resorption and annual maintenance. the success and survival rate of implants through the following parameters: pain; mobility; card index (ip); bleeding rate (is); probing depth (ps); probing bleeding (ss) that will be measured on four faces by implant: mesial, buccal, distal and lingual / palatine. for the evaluation of bone loss, a conventional periapical radiograph will be performed at the moment of patient recall. radiographs will be scanned and analyzed using image tool software to verify and determine the resulting linear distance between the implant shoulder and the bone crest. factors such as smoking, annual maintenance appointments will be related to the presence of peri-implantitis.

Eligibility criteria:
inclusion criteria: * after evaluation, individuals may be allocated into groups according to the characteristics observed, for example: carriers of single implants, patients with overdentures, individuals with systemic diseases, smokers. exclusion criteria: * individuals who need to use or suspend systemic medication to perform the proposed clinical exams will be excluded from the study.

Keywords: dental implants periodontal index peri-implantitis
inna-051 influenza challenge study

Conditions: Influenza Prophylaxis

Summary: this is a phase 2, randomized, double-blind, placebo-controlled study of inna-051 in healthy adults, administered prior to administration of an influenza challenge virus. this study will evaluate 2 active dose levels of inna-051 and placebo.

healthy participants will be administered 2 doses on inna-051 intra-nasally and subsequently administered influenza virus as a challenge. participants will be quarantined for 8 days. study assessments will be performed during this period and they will monitored for symptoms of influenza infection.

Eligibility criteria:
inclusion criteria: * provide written informed consent * 18 to 55 years (inclusive) at time of consent * in good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety * agree to use highly effective contraception exclusion criteria: * history of, or currently active, symptoms or signs suggestive of urt or lower respiratory tract (lrt) infection within 4 weeks prior to the first study visit * any history or evidence of any other clinically significant or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety) * participants who have smoked ≥10 pack years at any time * a total body weight ≤50 kg or body mass index (bmi) ≤18 kg/m2 or ≥35kg/m2. * pregnant or breast feeding * any significant abnormality altering the anatomy of the nose or nasopharynx that may interfere with the nasal assessments or viral challenge, clinically significant history of epistaxis, or any nasal or sinus surgery within 3 months of the first study visit * vaccinations within the 4 weeks prior to the planned date of first dosing with imp (10 days for sars-cov-2 vaccines, 6 months for influenza vaccine), or during the study * receipt of blood or blood products, or loss (including blood donations) of 470 ml or more of blood during the 3 months prior to dosing or planned in 3 months post. * receipt of any investigational product within 3 months (or 5 half-lives of the investigational product used in the other study, whichever is greater) prior to first dose with imp, or 3 imps within prior 12 months, or prior administration with a virus from the same virus family as the challenge virus, or prior participation in another respiratory viral challenge study in the preceding 3 months * confirmed positive test for drugs of abuse or cotinine, history or presence of alcohol addiction, or excessive consumption of xanthine-containing substances * a forced expiratory volume in 1 second (fev1) \<80% * positive hiv-1 or hiv-2 test, or positive test for hepatitis b or c
early-myo-af registry

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: the purpose of this registry is to depict the myocardial function improvement in af patients by integrated therapy and to assess the prognostic discrepancies of various intervention modalities. information will be collected prospectively in about 5000 af patients. subjects will be followed for up to 3 years.

this is a prospective, single-centered, non-randomized, observational registry study of af patients that undergo radio-frequency catheter ablation, left atrial appendage occlusion or surgical ablation. information of other medication intervention and clinical outcomes are also prospectively collected in the database. this project will establish a prospective registry of 5000 af patients with follow-ups of up to 3 years. the aim of the project will be as following: 1. to investigate pathophysiological changes of both atrial and ventricular myocardial function in af patients. 2. to identify clinical indices (including baseline, comorbidities, medication or operational interventions) that are associated with adverse clinical outcomes. 3. to spot potential therapeutical targets in the continuum of af: from risk-factors elimination to mortality and disability prevalence reduciton.

Eligibility criteria:
inclusion criteria: * eligible patients must be at least 18 years old at the time of enrollment. * patients who are clinically indicated catheter ablation or other interventions (laac or surgical maze procedure) for persistent or long standing persistent af. exclusion criteria: * contraindication for anticoagulation therapy * another (non-af) indication for long term anticoagulation * patients who have been enrolled as a respondent on other clinical studies * inability to attend scheduled, periodic office visits for follow-up * pregnancy * patient has a life expectancy of less than 6 months due to any condition.
an in depth study evaluating the experiences of patients in schizophrenia research

Conditions: Schizophrenia

Summary: historically, research participation has been biased toward certain demographics. however, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and negatively. several people will be invited to enroll in this study so that it may collect a variety of data about schizophrenia clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. the data collected from this study will be analyzed and used to improve the experiences of future schizophrenia patients who are recruited for medical trials.


Eligibility criteria:
inclusion criteria: * patient has self-identified as planning to enroll in a clinical trial * patient has been diagnosed with schizophrenia * patient is a minimum of 18 years or older exclusion criteria: * patient does not understand, sign, and return consent form * inability to perform regular electronic reporting * patient is pregnant

Keywords: schizophrenia
short spot versus long lesion stenting as best treatment for extensive occlusive sfa disease

Conditions: Peripheral Arterial Disease

Summary: since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (\> 1) short (focal; \> 1 and \< 5 cm) sfa lesions can be improved by spot stenting as compared to the use of one long stent. this study proposes to evaluate the endovascular treatment for patients with sfa lesions by comparing two strategies for patients with extensive occlusive sfa disease; 1) short spot (ss) stenting or 2) long lesion (ll) stenting.


Eligibility criteria:
inclusion criteria: * paod (abi \ 0.15 after exercise test), rutherford category 2, 3 or 4 * multiple (\>1) short (focal; \>1 and \< 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery * eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines * unilateral occlusive disease * age ≥ 18 exclusion criteria: * patients with paod rutherford category 5 and 6 * impaired inflow due to significant lesions in the arteries proximal to the sfa intended to treat * bilateral lesions with treatment indication * contra-indication for anticoagulant therapy * renal insufficiency (mdrd \< 50 ml/min) * life expectancy \< 6 months * known contrast allergy * pregnancy * unable to complete a questionnaire in the home language
observational study of adult participants with diabetic macular edema and suboptimal response to anti-vascular endothelial growth factor treated with dexamethasone intravitreal implant

Conditions: Diabetic Macular Edema

Summary: the dexamethasone 700 μg intravitreal implant (dex-i) delivers dexamethasone gradually to the retina over time. it is an approved drug for the treatment of dme. this study will assess adult participants with diabetic macular edema (dme) and suboptimal response to anti-vascular endothelial growth factor therapy that are treated with dex-i in the routine clinical setting. approximately 327 participants who are prescribed dex-i by their physicians will be enrolled at approximately 40 sites in approximately 10 countries globally. participants will be followed for 18 months post-dex-i implantation according to the routine clinical practice of the prescribing centers. only one eye per participant will be evaluated in the study. no additional burden for participants in this trial is expected.


Eligibility criteria:
inclusion criteria: * participant diagnosed with dme in the study eye * study eye has received at least 3 and no more than 9 anti-vegf injections in the 12 months prior to dex-i initiation * study eye newly prescribed dex-i. the prescribing decision lies with the physician and reflects their standard practice * participant showing a suboptimal response to anti-vegf at baseline in the study eye exclusion criteria: * any concomitant ocular or neurologic condition in the study eye that could cause macular edema or affect vision (except cataract) * history of ocular surgery within 60 days of baseline in the study eye * history of pan-retinal photocoagulation (prp) or sectorial photocoagulation in the study eye in the 3 months prior to baseline * significant media opacities in the study eye limiting optical coherence tomography (oct) quality * uncontrolled ocular hypertension (oht) or advanced glaucoma in the study eye * active ocular inflammation in either eye * study eyes that are aphakic with posterior capsule rent (pcr), anterior chamber intraocular lens (aciol), iris or scleral-fixed intraocular lens (iol) or history of complicated cataract surgery with pcr * prior use of intravitreal corticosteroids in the study eye * patients with contraindications to dex-i

Keywords: diabetic macular edema dme dexamethasone dexamethasone intravitreal implant ozurdex
optilume registry for treatment of stricture of the anterior urethra

Conditions: Anterior Urethral Stricture, Male

Summary: the purpose of this registry is verifying the continued safety and effectiveness of the optilume dcb clinical use in patients undergoing dilation of the urethral stricture.

after being informed about the registry and potential risks, all patients providing written informed consent will undergo urethral dilation using the optilume drug coated balloon (standard of care procedure). at 3, 6, 12 months, and annually 2 to 5 years after treatment patients will be invited to return to the hospital and several assessments will be performed, including questionnaires, if this is part of their standard care.

Eligibility criteria:
inclusion criteria: 1. male subjects ≥ 18 years old 2. subject diagnosed with a recurrent stricture ≤3cm in the anterior urethra that plans to be treated with optilume® dcb in accordance with the approved instructions for use. 3. subject provides written informed consent using an approved informed consent form (icf) and is willing to comply with standard follow-up assessments. exclusion criteria: 1. subjects with a known hypersensitivity to paclitaxel or structurally related compounds. 2. subject is unwilling to abstain or use a condom for 30 days after the procedure. 3. subject is unwilling to use highly effective contraception for 6 months after the procedure if partner is of childbearing potential. 4. subjects with a history of carcinoma of the genitourinary system (e.g., kidney, bladder, prostate, urethra, testes) that is not considered in complete remission.
neuroaxial blokade and blood pressure

Conditions: Hypovolemia

Summary: the effect of individualized fluid optimization during neuroaxial blockade has not been evaluated. the investigators evaluated if if stroke decrease 15 min after activation of neuroaxial blockade and whether sv could be optimized to pre activation values.

the purpose of this study is to evaluate sv maximization with aid of the lidco system which is a minimal invasive technique only requiring a venous and arterial line. we thereby attempt to cover the specific individual fluid deficit induced by neuroaxial blockade.

Eligibility criteria:
inclusion criteria: * neuroaxial blockade (thoracic) exclusion criteria: * weight below 40 kg * lithium therapy * type i diabetes or type ii requiring insulin
gao's triple eversion carotid endarterectomy

Conditions: Carotid Artery Stenosis

Summary: carotid endarterectomy (cea), an important surgical approach for managing carotid plaque, has evolved over more than 70 years but still cannot be applied to all tandem carotid lesions (tcls) because of the wide range of these lesions. herein, the investigators introduce an innovative cea, gao's triple eversion cea (gte-cea), for the treatment of tcls.

the investigators retrospectively reviewed the charts of patients who underwent gte-cea performed by the same group of vascular surgeons since 17 september, 2021. patients who did not meet the diagnostic criteria for carotid artery stenosis (cas); those with asymptomatic cas \< 50%, preoperatively confirmed by digital subtraction angiography (dsa) or computed tomography angiography (cta); and those with stenosis at the opening of the common carotid artery (cca) were excluded from our study.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for tcl stenosis. * above 70% asymptomatic cca and ica stenosis or \> 50% symptomatic cas confirmed by dsa or cta before surgery exclusion criteria: * did not meet the diagnostic criteria for cas * asymptomatic cas \< 50% (as confirmed by dsa or cta before surgery) * with stenosis at the opening of the cca.

Keywords: carotid artery stenosis tandem carotid lesion
study of hc-58 in upper limb hemiplegic patients after stroke

Conditions: Severe Upper Limb Hemiplegia

Summary: the purpose of this study is to investigate the efficacy and safety of hc-58 in patients with severe upper limb hemiplegia following stroke.


Eligibility criteria:
inclusion criteria: * patients with severe upper limb hemiplegia after stroke * within 28 days after stroke at enrollment exclusion criteria: * patients with sensory loss between shoulder and hand on paralyzed side * patients with pain between shoulder and hand on paralysed side which affects medical rehabilitation
quantified analysis of neuronal recovery using myelin imaging after robot assisted upper arm training in subacute stroke patients

Conditions: Stroke

Summary: * quantitative assessment method developed for brain plasticity through disability rehabilitation using a brain imaging technique. * development of brain imaging technology to improve understanding of brain plasticity during rehabilitation and to improve the efficiency of rehabilitation treatment for people with brain injury. ○ development of the latest brain function image analysis algorithm and data processing technology * development of new technology for imaging brain plasticity in addition to existing functional imaging technology and diffuse imaging technology (example: myelinated brain imaging technology, susceptibility imaging (swi) technology) * development of image reconstruction software technology using new image technology * multi-image and repeated shot data processing technology, wheat analysis technology development (example: 3d registration technology, automated segmentation technology) * conducted clinical research on clinical quantitative evaluation of brain plasticity due to rehabilitation treatment * recruitment of a group of patients for pursuing plasticity through rehabilitation among stroke patients (estimating the number of sample patients by setting a specific patient group and analyzing statistical power) * image-based brain change analysis through patient rehabilitation and before and after imaging * comparative analysis through securing a control group and activating the control group. derivation of clinical relevance through comparison with rehabilitation process


Eligibility criteria:
inclusion criteria: 1. less than 6 months after onset of the stroke 2. have fma score greater than 7 3. have confirmed that the integrity of the corticospinal tract (cst) is preserved in diffusion tensor imaging (dti) taken using 4. over 20 years of age 5. can understand and participated in study 6. consented to this study in writing or verbally exclusion criteria: 1. quadriplegia 2. past history of stroke 3. past history of musculoskeletal disease or history of neurological diseases 4. have a history of injury to the upper limb and upper chest, surgery, or peripheral nerve damage 5. have skin ulcers or skin diseases such as open wounds that have difficulty applying rat 6. pregnant woman 7. if it is judged that this clinical participation is not appropriate according to the judgment of medical doctor
acl reconstruction with the tls technique

Conditions: Joint Trauma

Summary: this is a non-interventional study to retrospectively validate the technical use tls (tape locking screw) in the anterior cruciate ligament. the investigators goal is to test the validity of the technique and its positive influence on the resumption of sporting activities in relation to the existing literature.


Eligibility criteria:
inclusion criteria: * patients over 18 years * patients operated in the service in 2014 to care for end-stage knee osteoarthritis by implantation of a total knee prosthesis. exclusion criteria: * patients under 18 years

Keywords: anterior cruciate ligament tape locking screw lca joint trauma
lampp trial for peripheral and cutaneous t-cell lymphoma

Conditions: T-Cell Lymphoma

Summary: peripheral t cell lymphoma and advanced cutaneous t cell lymphomas are aggressive and refractory diseases that are generally treated with chemotherapy. despite current treatment modalities, only a subset of patients will be cured by the treatment. in this study, four chemotherapeutic agents (l-asparaginase, methotrexate, doxil, and prednisone) will be administered in a combination regimen for patients with relapsed or refractory peripheral and/or advanced cutaneous t cell lymphoma. each one of these individual drugs have been shown to have activity to lymphomas. the objective of the study is to determine if the combination of these chemotherapy agents results in higher response and cure rates in this patient population. this will be a single institutional study which will included 32 patients in the peripheral t cell lymphoma group and 32 patients in the cutaneous t cell lymphoma group.

peripheral t cell lymphoma and advanced cutaneous t cell lymphomas are aggressive and refractory diseases that are generally treated with chemotherapy. despite current treatment modalities, only a subset of patients will be cured by the treatment. in this study, four chemotherapeutic agents (l-asparaginase, methotrexate, doxil, and prednisone) will be administered in a combination regimen for patients with relapsed or refractory peripheral and/or advanced cutaneous t cell lymphoma. each one of these individual drugs have been shown to have activity to lymphomas. the objective of the study is to determine if the combination of these chemotherapy agents results in higher response and cure rates in this patient population. this will be a single institutional study which will included 32 patients in the peripheral t cell lymphoma group and 32 patients in the cutaneous t cell lymphoma group.

Eligibility criteria:
inclusion: patients must be at least 18 years of age. histologically confirmed (including immunohistochemistry) diagnosis of t-cell lymphoma by skin biopsy or visceral/lymph node biopsy or bone marrow aspirate/biopsy life expectancy of more than 3 months. exclusion: uncontrolled diabetes mellitus active or serious infections uncontrolled with antibiotics concurrent treatment, radiation or investigational treatment. 5.2.6 significant underlying cardiac disease, including unstable angina, myocardial infarction less than 6 months before starting study, congestive failure of any cause

Keywords: t-cell lymphomas
testing of innocuousness of benzalkonium chloride on the eye concerning possible growth of langerhans cells

Conditions: Eye Diseases

Summary: the study analysis the influence of benzalkonium chloride on the density of antigen presenting langerhans cells. this is achieved in a double blind randomized study using in-vivo confocal microscopy to identify and quantify langerhans cells of the human cornea in its central and peripheral part. this study design is based on observations with raised langerhans cell density after the application of benzalkonium chloride containing eye drops in glaucoma patients.


Eligibility criteria:
inclusion criteria: * healthy probands exclusion criteria: * eye diseases * pregnancy and lactation period * drug dependency

Keywords: growth of dendritic cells prevention